David Ricks

Early Life & Education

David A. Ricks was born in 1967 and grew up in the United States with a strong foundation in science, business, and public service. His formative years were shaped by an intellectual curiosity and a drive to make a meaningful impact on the world — qualities that would eventually lead him to the forefront of the global pharmaceutical industry.

Ricks earned his Bachelor of Science degree from Purdue University in 1990, majoring in Industrial Management. The rigorous engineering and business curriculum at Purdue provided him with a strong analytical foundation and a practical, results-oriented approach to problem-solving. After beginning his career, Ricks returned to graduate school and completed his Master of Business Administration from the Kelley School of Business at Indiana University in 1996, concentrating in Marketing and Finance. This combination of technical and business education equipped him uniquely for a career in the pharmaceutical industry, where scientific innovation and commercial strategy must work hand in hand.

Career Journey

David Ricks' career path reflects a deliberate progression through increasingly complex leadership roles, building deep expertise in both the science and business of pharmaceuticals. Before joining Eli Lilly, Ricks began his career at IBM in New York as an account representative, gaining early experience in technology sales and client management.

In 1996, after completing his MBA, Ricks joined Eli Lilly and Company as a business development associate. Over the next two decades, he rose through the ranks of the Indianapolis-based pharmaceutical giant, holding key leadership positions across the company's domestic and international operations.

• Account Representative, IBM (1990–1994) — Began his career in technology sales in New York City
• Business Development Associate, Eli Lilly (1996–2001) — Joined Lilly after completing his MBA and held management roles in U.S. marketing and sales
• President and General Manager, Eli Lilly China (2008–2010) — Led the company's operations in one of the world's largest and fastest-growing pharmaceutical markets
• President, Eli Lilly USA (2010–2012) — Oversaw the company's domestic commercial operations
• President, Lilly Bio-Medicines (2012–2016) — Led the company's largest business unit, overseeing drug development and commercial operations in neuroscience, pain, and immunology
• Chairman & CEO, Eli Lilly (2017–Present) — Has led the company through a period of unprecedented growth and scientific achievement

Leadership at Eli Lilly

In January 2017, David Ricks became the chief executive officer of Eli Lilly and Company, and was subsequently appointed chairman of the board. He inherited a company with a proud 140-year history but one that was facing significant challenges: key patents were expiring, the drug development pipeline needed strengthening, and the competitive landscape was intensifying across all of Lilly's therapeutic areas.

Ricks moved quickly to reshape Lilly's strategic direction. He made bold decisions to focus the company's research and development efforts on areas where Lilly could achieve the greatest scientific and commercial impact, particularly in diabetes and metabolic diseases, oncology, immunology, and neuroscience. He invested heavily in the R&D pipeline while simultaneously streamlining operations and improving manufacturing capabilities.

The results of Ricks' strategic vision have been extraordinary. Under his leadership, Eli Lilly has become one of the most valuable pharmaceutical companies in the world, and in 2024 became the first healthcare company in history to reach a $1 trillion market capitalization. This milestone reflected both the company's strong financial performance and investor confidence in its long-term growth prospects.

Ricks has overseen the development and commercialization of several transformative medicines that have reshaped their respective therapeutic categories. His ability to balance scientific ambition with commercial discipline has positioned Lilly as a leader in multiple high-growth markets.

The GLP-1 Revolution

Perhaps the most significant achievement of David Ricks' tenure as CEO has been Eli Lilly's leadership in the development of GLP-1 receptor agonist therapies, which have transformed the global approach to treating diabetes and obesity. Under Ricks' leadership, Lilly developed and brought to market tirzepatide, a dual GIP/GLP-1 receptor agonist that has become one of the most commercially successful pharmaceutical products in history.

Marketed as Mounjaro for type 2 diabetes and Zepbound for obesity, tirzepatide has generated billions of dollars in revenue and has been credited with revolutionizing the treatment of metabolic disease. The clinical trial results for tirzepatide showed unprecedented levels of weight loss and glycemic control, establishing new benchmarks for what medical intervention could achieve in these conditions.

The commercial success of Mounjaro and Zepbound has been staggering. Demand for the medications initially outstripped supply, leading Lilly to invest billions of dollars in new manufacturing facilities to scale production. The GLP-1 category as a whole has become one of the largest and fastest-growing segments of the global pharmaceutical market, and Ricks' early strategic bet on this therapeutic area has positioned Lilly at the center of a healthcare revolution.

Beyond diabetes and obesity, Ricks has championed research into additional applications of GLP-1 therapies, including potential benefits for cardiovascular disease, sleep apnea, and other metabolic conditions. This expansion of the GLP-1 platform represents a significant opportunity for continued growth and patient impact.

Key Achievements & Milestones

• Led Eli Lilly to become the first healthcare company to reach a $1 trillion market capitalization
• Oversaw the development and launch of Mounjaro (tirzepatide) for type 2 diabetes, generating billions in annual revenue
• Launched Zepbound for obesity treatment, creating a new blockbuster franchise
• Secured FDA approval for Kisunla (donanemab) for early symptomatic Alzheimer's disease
• Delivered record R&D output with multiple breakthrough therapy designations across oncology, immunology, and neuroscience
• Invested billions in new manufacturing capacity to meet unprecedented demand for GLP-1 therapies
• Named Chief Executive magazine's CEO of the Year
• Total compensation of $29.2 million in 2024, reflecting strong company performance

Leadership Philosophy

David Ricks' leadership philosophy is grounded in the belief that pharmaceutical companies have a unique responsibility to improve human health through scientific innovation. He has consistently emphasized that Lilly's primary purpose is to develop medicines that make a meaningful difference in the lives of patients, and that commercial success should flow naturally from delivering on that mission.

Ricks is known for his disciplined approach to capital allocation and portfolio management. He has been willing to make difficult decisions about where to invest and where to divest, focusing Lilly's resources on therapeutic areas where the company has the greatest scientific expertise and commercial potential. This strategic discipline has been a key factor in Lilly's outperformance relative to its pharmaceutical industry peers.

He has also been a vocal advocate for the importance of research and development investment in the pharmaceutical industry. Ricks has argued that sustained investment in R&D, even during periods of financial pressure, is essential for long-term success and for addressing unmet medical needs. Under his leadership, Lilly has consistently invested approximately 25 percent of its revenue in R&D, among the highest ratios in the industry.

Industry Impact

David Ricks has had a profound impact on the pharmaceutical industry through his leadership of Eli Lilly's GLP-1 program and his advocacy for innovation-driven growth strategies. The success of Mounjaro and Zepbound has not only transformed Eli Lilly but has reshaped the entire pharmaceutical landscape, demonstrating the enormous commercial potential of medicines that address large, underserved patient populations.

The GLP-1 revolution that Ricks has helped lead has broader implications for healthcare systems worldwide. By providing effective pharmaceutical interventions for obesity — a condition that affects hundreds of millions of people globally — these medicines have the potential to reduce the burden of obesity-related diseases including heart disease, stroke, and certain cancers, potentially saving healthcare systems billions of dollars in downstream costs.

Ricks has also been influential in shaping industry discussions around drug pricing, manufacturing capacity, and access to medicines. He has advocated for policies that balance the need for innovation incentives with the imperative of ensuring that patients can access the medicines they need.

Awards & Recognition

• Named CEO of the Year by Chief Executive magazine
• Regularly ranked among the most influential leaders in the pharmaceutical industry
• Member of the Board of Directors, Adobe Inc.
• Member of the Purdue University Board of Trustees
• Recognized for leading Eli Lilly to its first $1 trillion market capitalization

Personal Life

David Ricks resides in the Indianapolis metropolitan area, near Eli Lilly's global headquarters. He is married and has maintained deep roots in Indiana throughout his career, returning to the state after his international assignments. Ricks is a dedicated supporter of the Purdue University community and has served on the university's Board of Trustees, giving back to the institution that launched his career.

Ricks is known among colleagues for his thoughtful, understated leadership style and his genuine passion for the science behind Lilly's medicines. He frequently speaks about the personal stories of patients whose lives have been improved by Lilly's products, reflecting a deep commitment to the company's mission of making life better for people around the world.

Vision for the Future

David Ricks has articulated an ambitious vision for Eli Lilly's continued growth and scientific impact. He sees the company's GLP-1 platform as just the beginning of a broader revolution in metabolic medicine, with ongoing research exploring additional applications of incretin-based therapies across cardiovascular disease, liver disease, and other conditions.

In neuroscience, Ricks has positioned Lilly as a leader in Alzheimer's disease treatment following the approval of Kisunla, and the company continues to invest in next-generation therapies for neurodegenerative diseases. In oncology, Lilly's pipeline includes several promising candidates in areas such as breast cancer and solid tumors.

Ricks has also emphasized the importance of expanding access to Lilly's medicines globally, including in lower-income countries where the burden of metabolic disease is growing rapidly. He has committed to investing in manufacturing capacity and developing partnerships that can help bring Lilly's innovations to patients who need them most, regardless of geography or economic status.